Health (OTC Drugs)
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Regulation/Legislation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Regulation, Legislation & Health
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
New York Begins Restricting Sales Of Supplements, OTC Drugs For Weight Loss, Bodybuilding
Southern New York district judge rejects CRN’s arguments to block regulation from taking effect, but agrees with trade group and its members that they have standing to challenge the regulation. CRN complaint challenging law will continue in the district court.
Largest PBMs Eliminate Consumers’ Cost Sharing For Opill On Most Commercial Plans
Decisions by “big three” PBMs suggest they’re taking proactive steps to comply with potential HRSA rulemaking to require most health plans, under Affordable Care Act regulations, to cover Opill and other types of OTC birth control without cost sharing.
Business Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Deals & Health
‘Meaningful Revenues’ In 2023 Mark Strategic Milestone As Futura Looks To Future
Futura recorded its first notable revenues last year, generated by the launch of its Eroxon erectile dysfunction gel in the UK and Europe, marking the company's transition from an R&D startup to a consumer healthcare player in its own right. To mark the occasion, CEO James Barder outlines a new strategy, with a focus on innovation in sexual wellness, further global partnerships and sustained profitability.
Japan's Rohto Snaps Up TCM Specialist To Grow In Asia
In a deal worth around $600m, Rohto Pharmaceutical is poised to expand its dietary supplements offering in Southeast Asia through the acquisition of a controlling stake in Singapore's Eu Yan Sang.
Karo Expands Intimate Health Offering With Bayer's Proctosedyl
Sweden's Karo has struck its second deal in six months bringing in the Proctosedyl hemorrhoid brand from Bayer.
Latest From Business Strategies & Health
Qunol Acquisition Gets Sanofi CHC Off To Flying Start
Sanofi CHC sales up 9% in Q1 driven by addition of US healthy aging supplement brand Qunol. Separately, the Paris-based firm has reached an agreement in principle to resolve the vast majority of Zantac personal injury state court cases in the US.
US Women’s Health Sector: Hip Hop Stars Invest In Proov, Good Clean Love Names CEO
At-home fertility-related hormone test developer Proov sells equity stake to entertainers and expectant parents Ashanti and Nelly; sexual and vaginal health product firm Good Clean Love moves from its founder as leader to a consumer health industry executive.
Reckitt Sees R&D Investment Translate To Volume Growth
R&D investments behind consumer health brands such as Nurofen and Durex pay off for Reckitt in Q1 as it sees volume growth across majority of portfolio.
Latest From Sales & Earnings & Health
Qunol Acquisition Gets Sanofi CHC Off To Flying Start
Sanofi CHC sales up 9% in Q1 driven by addition of US healthy aging supplement brand Qunol. Separately, the Paris-based firm has reached an agreement in principle to resolve the vast majority of Zantac personal injury state court cases in the US.
Reckitt Sees R&D Investment Translate To Volume Growth
R&D investments behind consumer health brands such as Nurofen and Durex pay off for Reckitt in Q1 as it sees volume growth across majority of portfolio.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Latest From Legal Issues & Health
L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts
Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.
Cue The Class Actions! Plaintiffs React To Valisure’s Benzene Findings In Acne Drug Products
J&J, Target and Walgreens face class action complaints in California federal courts for economic harms caused by their sale of benzoyl peroxide-containing acne treatments, following Valisure’s 5 March citizen petition to the US FDA on findings of high levels of benzene in such products.
US FDA Should Reload Field Force To Target OTC Adulteration, Former Chief Counsel Hutt Says
Habitually noncompliant companies are laughing at FDA, Peter Barton Hutt says.
Marketing Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Launches & Health
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.
Latest From Ad Campaigns & Health
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
Over The Counter 22 Apr 2024: Helping Consumers ‘Tune In’ To Reliable Health Information, With Kaizo PR's Anita Nahal
“Consumers are rewriting the rules when it comes to where they are going for information and the type of information they are looking for,” reports Kaizo’s Anita Nahal, speaking to HBW Insight’s Over the Counter podcast about the agency’s latest Communicating Health Messages report. Trust in social media has increased, and personal beliefs and lived experiences are playing a larger role in shaping attitudes to health information, explains Nahal, who is director at the London-based PR agency. However, consumers are also continuing to “tune-out” from health messages and be less critical of sources. To help consumers navigate this new reality, consumer health companies need to adapt, rethink and reset their communication strategies, Nahal advises.
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Latest From Ad Complaints & Health
EU Firms To Pre-Approve Green Claims Or Face Minimum 4% Annual Turnover Fine
Exclusion from procurement processes, confiscation of revenues, and a fine of at least 4% of annual turnover are some of the penalties the European Parliament is considering for greenwashing as part of its position on the EU Green Claims Directive.
Take Care With ‘Health Lite’ Claims
Some advertisers try to avoid scrutiny of regulators and the National Advertising Division when making health-related claims by making a claim “softer.” Annie Ugurlayan, NAD’s assistant director, offers advice on assuring substantiation and a health claim match.
ASA Files: How Not To Advertise A Digital Health App In The UK
ADHD-management software Happyo falls foul of UK advertising rules in a recent ASA case. The lesson: if in the UK the intended use of a digital health app is the diagnosis of a serious medical condition, supervision by a healthcare professional such as a doctor is likely to be necessary, in which case advertising to the public would also be prohibited.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.